Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Omega-3 Fatty Acids on Aspirin Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Willing to participate by providing informed consent and committing to complete the study. This includes adhering to the study diet.~* No chronic disease by history and based on a complete blood count and comprehensive metabolic profile.~* Commitment to not taking aspirin, non-steroidal anti-inflammatory medications, and to limit fish intake to ≤2 meals during the 7 days prior to each CRC study period. They will also need to abstain from taking a list of over-the-counter medications that include aspirin. For the duration of the study, they will also be asked to abstain from taking fish and flax seed oil supplements.~Exclusion Criteria:~* Reports the presence of chronic disease (e.g. cardiovascular, renal, hepatic, neurodegenerative, neoplastic, metabolic {diabetes}, hypertension).~* Reports taking a systemic medication chronically.~* History of serious adverse reaction or allergy to aspirin or fish oil.~* Baseline platelet count \<100 000 or \>500 000, hematocrit \<30%, or white blood cell count \>20 000.~* Any abnormality from a screening CBC and complete blood count that suggests acute or chronic disease.~* Nicotine user.~* History of alcohol abuse~* Pregnancy by history or urine/serum pregnancy test~* History of intestinal malabsorption syndrome including gastric bypass surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Placebo, Lovaza, Aspirin, Both Aspirin and Lovaza (Type: EXPERIMENTAL): First Placebo, then 4 grams of Lovaza, then 81mg of Aspirin, then both 4 grams of Lovaza and 81 mg of Aspirin
- Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo (Type: EXPERIMENTAL): First 81mg of Aspirin, then 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo
- Lovaza, Both Aspirin and Lovaza, Placebo, Aspirin (Type: EXPERIMENTAL): First 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 81mg of Aspirin
- Both Aspirin and Lovaza, Placebo, Lovaza, Aspirin (Type: EXPERIMENTAL): First both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 4 grams of Lovaza, then 81mg of Aspirin

Based on this trial design, predict the completion outcome and termination type (if applicable).